{"id":127866,"date":"2025-07-21T06:00:34","date_gmt":"2025-07-21T10:00:34","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/?p=127866"},"modified":"2025-07-19T14:22:30","modified_gmt":"2025-07-19T18:22:30","slug":"adhd-medication-tied-to-homicidal-thoughts-cchr-demands-urgent-consumer-alerts","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/adhd-medication-tied-to-homicidal-thoughts-cchr-demands-urgent-consumer-alerts\/","title":{"rendered":"ADHD Medication Tied to Homicidal Thoughts – CCHR Demands Urgent Consumer Alerts"},"content":{"rendered":"

LOS ANGELES, Calif., July 21, 2025 (SEND2PRESS NEWSWIRE) \u2013 The mental health industry watchdog Citizens Commission on Human Rights International (CCHR)<\/a> is calling for sweeping reforms to inform families and patients about hidden, potentially life-threatening side effects linked to widely prescribed Attention Deficit Hyperactivity Disorder (ADHD) drugs. The demand follows alarming new regulatory agency warnings from Australia and Germany about atomoxetine, a \u201cnon-stimulant\u201d ADHD medication, which is now linked to homicidal thoughts in both children and adults.<\/p>\n

\"The
Image caption: The mounting international warnings about ADHD drugs highlight a failure of informed consent on a massive scale. This is a complete breakdown of a system that should uphold the highest standard of informed consent.<\/em><\/p>\n

In May, Australia\u2019s Therapeutic Goods Administration (TGA) issued an urgent update to the product information for atomoxetine hydrochloride, warning of the risk of \u201caggressive behavior including homicidal ideation\u201d in children and adults.[1] A separate alert in June emphasized \u201csevere cases\u201d of \u201cphysical assault, or threatening behavior and thoughts of harming others.\u201d[2] The updated product information also says that \u201caggressive behavior or hostility was more frequently observed in clinical trials among children, adolescents, and adults treated with atomoxetine compared to placebo.\u201d[3]<\/p>\n

In February, Germany\u2019s Federal Institute for Drugs and Medical Devices released its own warning, referencing the European Medicines Agency\u2019s Pharmacovigilance Risk Assessment Committee (PRAC), which determined a \u201cpossible connection\u201d between atomoxetine and cases of serotonin syndrome\u2014a potentially fatal condition causing toxicity\u2014as well as physical assaults, threatening behavior, and homicidal thoughts.[4]<\/p>\n

\u201cThe stakes are enormous,\u201d said Jan Eastgate, president of CCHR International. \u201cThe Atomoxetine Hydrochloride Market was valued at $1.2 billion last year, and the U.S. ADHD drug market overall has ballooned to $20 billion annually. Yet consumers remain uninformed of the magnitude of these risks.\u201d<\/p>\n

New studies confirm that atomoxetine\u2019s risks are a small part of much larger concerns with ADHD drugs:<\/p>\n